Oral delivery of therapeutically effective LNA oligonucleotides
The invention provides for LNA oligomers, for the treatment of a metabolic or liver disorder, wherein the LNA oligomer is administered orally in a unit dose of less than 50 mgs/kg, wherein the LNA oligomer is administered in the presence of a penetration (permeation) enhancer.
1. A method for treating a disorder selected from the group consisting of hyperlipidemia, HDL/LDL cholesterol imbalance, dyslipidemia, coronary artery disease (CAD), coronary heart disease (CHD), and atherosclerosis, comprising orally administering a composition comprising an LNA oligomer that targets ApoB and a penetration enhancer selected from the group consisting of: a fatty acid, a bile acid, a chelating agent, an anionic cationic surfactant, and a non-chelating non-surfactant, or pharmaceutically acceptable salts thereof, wherein the ratio between the penetration enhancer and LNA oligomer is at least 5:1 (w/w), and wherein the LNA oligomer is administered at less than 50 mg/kg.
2. The method of claim 1 wherein the LNA oligomer is between 8 and 16 nucleobases in length.
3. The method of claim 1 wherein the human oral bioavailability of the LNA oligomer is at least 10%.
4. The method of claim 1 wherein the penetration enhancer is reversible paracellular junction modulator.
5. The method of claim 1 wherein the ratio of penetration enhancer to LNA oligomer is at least 10:1 (w/w).
6. The method of claim 1 wherein in the oral administration is preceded by intravenous administration of the LNA oligomer.
7. The method of claim 1 wherein the oral administration reduces the level of serum cholesterol.
8. The method of claim 1 wherein the oral administration reduces the level of serum HDL.
9. A method for inhibiting ApoB expression, comprising orally administering a composition comprising an LNA oligomer that targets ApoB and a penetration enhancer selected from the group consisting of: a fatty acid, a bile acid, a chelating agent, an anionic cationic surfactant, and a non-chelating non-surfactant, or pharmaceutically acceptable salts thereof, wherein the ratio between the penetration enhancer and LNA oligomer is at least 5:1 (w/w), and wherein the LNA oligomer is administered at less than 50 mg/kg.
10. The method of claim 9 wherein the oral administration reduces the level of serum cholesterol.
11. The method of claim 9 wherein the oral administration reduces the level of serum HDL.
12. The method of claim 1 wherein the dyslipidemia is selected from the group consisting of: familial combined hyperlipidemia (FCHL), acquired hyperlipidemia, hypercholesterolemia, and statin-resistant hypercholesterolemia.
13. The method of claim 1 or 9 wherein the LNA oligomer is administered at a dose of less than 10 mg/kg.
14. The method of claim 1 or 9 wherein the LNA oligomer is administered with a drink or taken with food.
15. The method of claim 1 or 9 , wherein the oral administration is preceded by a parenteral pre-dose of the LNA oligomer, which is administered at least one day prior to the oral administration of the LNA oligomer.
16. The method of claim 1 or 9 , wherein the LNA oligomer is orally administered at least once per week.
17. The method of claim 1 or 9 , wherein the LAN oligomer is a gapmer.